Lexaria Bioscience Corp.
LEXX Healthcare Biotechnology
Lexaria Bioscience Corp.’s revenue for fiscal 2025 (year ended August 2025) was $705,900.00, up 52.0% from fiscal 2024. In the quarter to May 2026, revenue fell 89.1%, EPS grew 61.9% and free cash flow grew 53.9%, each against the same quarter a year earlier. Revenue growth for three consecutive years.
Follow LEXX
Lexaria Bioscience Corp. (LEXX) Altman Z-score
Lexaria Bioscience Corp.'s Altman Z-score for fiscal 2025 is −23.89, in the distress zone (below 1.81).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2025 | −23.89 | (38.63) |
| FY2024 | 14.74 | 31.38 |
| FY2023 | −16.64 | (59.85) |
| FY2022 | 43.21 | (33.83) |
| FY2021 | 77.04 | 91.49 |
| FY2020 | −14.44 | (10.87) |
| FY2019 | −3.57 | (118.72) |
| FY2018 | 115.15 | 149.87 |
| FY2016 | −34.71 | — |
How fiscal 2025’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | 0.47 | — | 0.57 | |
| Retained earnings / total assets | (15.20) | — | −21.28 | |
| EBIT / total assets | (2.85) | — | −9.39 | |
| Market value of equity / total liabilities | 10.08 | — | 6.05 | |
| Sales / total assets | 0.17 | — | 0.17 | |
| Altman Z-score | Distress zone | −23.89 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Distress zone | −63.83 | ||
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| EVGN Evogene Ltd. compare | −20.5× |
| LEXX Lexaria Bioscience Corp. | −23.9× |
| TRAW Traws Pharma, Inc. compare | −89.5× |
| TCRT Alaunos Therapeutics, Inc. compare | −436× |
| ENVB Enveric Biosciences, Inc. compare | — |
| NRSN NeuroSense Therapeutics Ltd. compare | — |
| FBLG FibroBiologics Inc. compare | — |
| ALZN Alzamend Neuro, Inc. compare | — |
| ACXP Acurx Pharmaceuticals, Inc. compare | — |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets